TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07499544: A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Sponsor: Huahui Health · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 160 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,377,684

Rescue Site Savings

+$918,456

Unlock Full NCT07499544 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07499544 Rescue Dossier →